

**JUSTIFICATION FOR SINGLE SOURCE AWARDS IAW FAR 13.106-1  
 (OVER MICRO-PURCHASE THRESHOLD(\$3K) BUT NOT EXCEEDING THE SAT (\$150K))**

IAW FAR 13.104, COs must promote competition to the maximum extent practicable to obtain supplies and services from the source whose offer is the most advantageous to the Government, considering the administrative cost of the purchase. When competition is not practicable, IAW FAR 13.106-1(b), COs solicit from a single source for purchases not exceeding the simplified acquisition threshold. COs may solicit from one source if the CO determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name or industrial mobilization). IAW FAR 13.106-3(b)(3), COs are required to include additional statements **explaining the absence of competition** (see 13.106-1 for brand name purchases) if only one source is solicited and the acquisition does not exceed the simplified acquisition threshold (does not apply to an acquisition of utility services available from only one source) or supporting the award decision if other than price-related factors were considered in selecting the supplier. This template when completed can be used to document single source awards IAW FAR 13.106-3(b)(3). Note: Statements such as "only known source" or "only source which can meet the required delivery date" are inadequate to support a sole source purchase.

<b>1. PURCHASE REQUEST OR REQUISITION NUMBER:</b> 600-17-1-114-0004	<b>1A. PROJECT/TASK NUMBER</b> N/A	<b>1B. ESTIMATED AMOUNT:</b> 43,878.30
--	---------------------------------------	---

**2. BRIEF DESCRIPTION OF SUPPLIES OR SERVICES REQUIRED AND THE INTENDED USE:** The Network Contracting Office, NCO22, 4811 Airport Plaza Drive, Suite 600, Long Beach, CA, as requested by VA Long Beach Healthcare System (VALBHS), Nuclear Medicine Service, will enter into a contract that requires "Justification for Other Than Full and Open Competition" for purchase request to provide I123 DA TSCAN radiopharmaceutical for direct patient treatment within the Nuclear Medicine Service.

**3. UNIQUE CHARACTERISTICS THAT LIMIT AVAILABILITY TO ONLY ONE SOURCE, WITH THE REASON NO OTHER SUPPLIES OR SERVICES CAN BE USED:**

GE Healthcare is the sole provider for proprietary and manufacturer of the I123 DATSCAN radiopharmaceutical. I123 DATSCAN (Ioflupane I 123 Injection) is a radiopharmaceutical indicated for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging to assist in the evaluation of adult patients with suspected Parkinsonian syndromes (PS). There are no authorized resellers.

IAW FAR 13.106—1(b)

**4. REASON THAT SUGGESTED SOURCE IS THE ONLY SOURCE, WHICH CAN PROVIDE THE SUPPLIES OR SERVICES:**

GE Healthcare is the sole provider for proprietary and manufacturer of the I123 DATSCAN radiopharmaceutical, which is indicated for treatment of adult patients with suspected Parkinsonian syndromes.


**5. DESCRIPTION OF MARKET RESEARCH CONDUCTED AND RESULTS OR STATEMENT WHY IT WAS NOT CONDUCTED:**

Market Research was conducted through Federal Business Opportunities (FBO) as a set-aside for SDVOSB/VOSB, resulting with no responses; NAC tools, GSA Advantage and VETBIZ. One large business responded to FBO, which was GE Healthcare. Therefore, research shows that GE Healthcare owns the proprietary rights and is the sole source provider for the I123 DATSCAN radiopharmaceutical.

No other sources are able to satisfy the needs of the government.

**6. Contracting Officer's Certification:** *Purchase is approved in accordance with FAR13.106-1(b). I certify that the foregoing justification is accurate and complete to the best of my knowledge and belief.*

Signature: \_\_\_\_\_



Date: \_\_\_\_\_

9-2-16

Name: Rosetta Quintons

Title: Contracting Officer, NCO22

Facility: Network Contracting Office 22